Stephen Diggle has been working in finance since 1986.
After 15 years working at international Investment Banks in London, Sydney, and Hong Kong he was one of two founders of Artradis Fund Management, a Singapore-based hedge fund company which launched in 2002 with US$4m and peaked at nearly US$5b late in 2008. Artradis was multi-award winning and for some time the largest and most successful hedge fund in Asia, making US$2.7bn for investors between 2002 and 2009, especially during the financial crisis of 2008 when it was most successful.
The hedge fund closed in March 2010, returning cash in full to all investors and being one of the few multi $bn hedge funds never to have gated investors' capital. Following this, he founded Vulpes Investment Management, a family office-backed investment manager that runs a diverse portfolio of assets, including significant investments in U.K.-based biotechnology companies, where he acts as one of the two portfolio managers.
Vulpes has been an early investor in companies such as Scancell and Oxford Biomedica, providing capital at critical times to keep the companies afloat. With a decade of experience investing in this sector, he is more passionate than ever about finding undervalued biotech firms and helping them grow.
Stephen holds a Master's degree from the University of Oxford in Philosophy, Politics, and Economics.